Toxicological Profile for DDT, DDE, and DDD

April 2022

U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry
DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health
and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
# VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 2022</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>December 2019</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>November 2008</td>
<td>Addendum to the toxicological profile released</td>
</tr>
<tr>
<td>September 2002</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>May 1994</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>August 1990</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Obaid Faroon, D.V.M., Ph.D. (Lead)
Patricia Ruiz, Ph.D.
Dennis Jones, D.V.M., Ph.D.
Sam Keith, M.S., C.H.P.
Franco Scinicariello, M.D., M.P.H.

Kimberly Zaccaria, Ph.D., D.A.B.T
Mario Citra, Ph.D.
Deborah Herber, Ph.D.
Parker Honey, M.P.H.
Lisa Ingerman, Ph.D., D.A.B.T.
Fernando Llados, Ph.D.
Peter McClure, Ph.D., D.A.B.T.
Shelley Stevens, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice, EPA.

PEER REVIEWERS

1. George Howell III, Ph.D., Assistant Professor, Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University

2. Charles J. Everett, Ph.D., U.S. Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, South Carolina


These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.
The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
# CONTENTS

FOREWORD ............................................................................................................. ii
VERSION HISTORY ............................................................................................... v
CONTRIBUTORS & REVIEWERS ........................................................................ vi
CONTENTS .......................................................................................................... vii
LIST OF FIGURES ............................................................................................ x
LIST OF TABLES ............................................................................................... xi

## CHAPTER 1. RELEVANCE TO PUBLIC HEALTH
1.1 OVERVIEW AND U.S. EXPOSURES ............................................................. 1
1.2 SUMMARY OF HEALTH EFFECTS ............................................................. 3
1.3 MINIMAL RISK LEVELS (MRLs) ................................................................. 5

## CHAPTER 2. HEALTH EFFECTS
2.1 INTRODUCTION ........................................................................................... 15
2.2 DEATH .......................................................................................................... 72
2.3 BODY WEIGHT ............................................................................................. 75
2.4 RESPIRATORY ............................................................................................. 83
2.5 CARDIOVASCULAR .................................................................................... 85
2.6 GASTROINTESTINAL ............................................................................... 90
2.7 HEMATOLOGICAL ..................................................................................... 92
2.8 MUSCULOSKELETAL ................................................................................. 94
2.9 HEPATIC ..................................................................................................... 95
2.10 RENAL ....................................................................................................... 102
2.11 DERMAL .................................................................................................. 103
2.12 OCULAR ................................................................................................... 104
2.13 ENDOCRINE ............................................................................................. 104
2.14 IMMUNOLOGICAL .................................................................................... 116
2.15 NEUROLOGICAL ...................................................................................... 130
2.16 REPRODUCTIVE ....................................................................................... 154
2.17 DEVELOPMENTAL .................................................................................. 188
2.18 OTHER NONCANCER ............................................................................ 212
2.19 CANCER .................................................................................................... 229
2.20 GENOTOXICITY ....................................................................................... 244

## CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS
3.1 TOXICOKINETICS ..................................................................................... 256
3.1.1 Absorption ............................................................................................ 256
3.1.2 Distribution .......................................................................................... 257
3.1.3 Metabolism .......................................................................................... 260
3.1.4 Excretion .............................................................................................. 262
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 263
3.1.6 Animal-to-Human Extrapolations ......................................................... 272
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 273
3.3 BIOMARKERS OF EXPOSURE AND EFFECT ......................................... 276
3.3.1 Biomarkers of Exposure ...................................................................... 277
3.3.2 Biomarkers of Effect ........................................................................... 278
3.4 INTERACTIONS WITH OTHER CHEMICALS .......................................... 278
LIST OF FIGURES

1-1. Health Effects Following Oral Exposure to DDT, DDE, and DDD ......................................................... 4

1-2. Summary of Sensitive Targets of DDT, DDE, and DDD – Oral .......................................................... 13

2-1. Overview of the Number of Studies Examining DDT, DDE, and DDD Health Effects ...................... 19

2-2. Levels of Significant Exposure to DDT, DDE, and DDD – Oral .......................................................... 64

3-1. Proposed Metabolic Pathway of \( p,p' \)-DDT by Rat Liver Microsomes ........................................ 260

3-2. Proposed Metabolic Scheme Converting DDT to DDA, the Principal Metabolite Excreted in Rat Urine ................................................................. 261

3-3. Proposed Metabolic Pathway for the Conversion of \( p,p' \)-DDE to its Methylsulfone Derivative ................................................................. 262

3-4. Diagrammatic Representation of the Physiologically Based Pharmacokinetic Model for Gestation ........................................................................ 265

3-5. Diagrammatic Representation of the Physiologically Based Pharmacokinetic Model for the Lactating Dam and Nursing Pup ...................................... 266

3-6. Conceptual Representation of the Mother-Infant Physiologically Based Pharmacokinetic Model ........................................................................ 269

5-1. Number of NPL Sites with DDT, DDE, and DDD Contamination .................................................... 285

5-2. Sum of DDT-like Compounds in µg/kg Lipid in Pooled Human Samples from Different Countries ............................................................................ 345

6-1. Summary of Existing Health Effects Studies on DDT, DDE, and DDD By Route and Endpoint ........ 357
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for DDT, DDE, and DDD ................................................................. 14

2-1. Levels of Significant Exposure to DDT, DDE, and DDD – Oral ...................................................... 20

2-2. Summary of Studies of Associations between DDT Exposure Biometrics and Body Weight Status ................................................................. 76

2-3. Summary of Studies of Associations between DDT Exposure Biometrics and Cardiovascular Endpoints ............................................................................. 85

2-4. Summary of Studies of Associations between DDT Exposure Biometrics and Gastrointestinal Endpoints ......................................................................................... 90

2-5. Summary of Studies of Associations between DDT Exposure Biometrics and Hematological Endpoints .................................................................................... 92

2-6. Summary of Studies of Associations between DDT Exposure Biometrics and Musculoskeletal Endpoints ..................................................................................... 95

2-7. Summary of Studies of Associations between DDT Exposure Biometrics and Hepatic Endpoints ......................................................................................... 96

2-8. Summary of Studies of Associations Between DDT Exposure Biometrics in Adolescents or Adults and Serum Thyroid Hormone Levels ........................................... 105


2-10. Summary of Studies of Associations Between DDT Exposure Biometrics in Adults and Immunological Endpoints ................................................................................. 116

2-11. Summary of Studies of Associations between DDT Exposure Biometrics in Children and Immunological Endpoints ............................................................................ 117

2-12. Summary of Studies of Associations Between Maternal Serum, Cord Blood, or Milk DDT Exposure Metrics and Immunological Endpoints in Offspring .............................. 119

2-13. Summary of Neurological Perturbations in Adult or Adolescent Humans with DDT Exposure Biometrics ....................................................................................... 131

2-14. Summary of Studies of Associations between Maternal Serum, Cord Blood, Breast Milk, or Placental DDT Exposure Biometrics and Neurological Outcomes in Offspring ............................. 133

2-15. Summary of Reproductive Outcomes in Adult Humans with DDT Exposure Biometrics ............ 154

2-16. Summary of Studies of Associations between Human DDT Exposure Metrics in Child and Adolescent Serum and Reproductive Endpoints ....................................................................... 168
5-9. Mean Daily Intake of DDT Per Unit Body Weight (μg/kg body weight/day) for Various Age Groups in the United States ................................................................. 334

5-10. Geometric Mean and Selected Percentiles of Serum p,p′-DDT (Lipid Adjusted in ng/g of Lipid or ppb on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 ..................................................... 338

5-11. Geometric Mean and Selected Percentiles of Serum p,p′-DDT (Whole Weight Lipid in ng/g of Serum or ppb) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 ................................................................................. 339

5-12. Geometric Mean and Selected Percentiles of p,p′-DDE (Lipid Adjusted in ng/g of Lipid or ppb on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 ................................................................................. 341

5-13. Geometric Mean and Selected Percentiles of p,p′-DDE (Whole Weight in ng/g of Serum or ppb) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 ................................................................. 342

5-14. Levels of DDT Compounds in Human Milk, Blood, and Tissues ................................................................. 346

6-1. Ongoing Studies on DDT, DDE, and DDD .......................................................................................... 367

7-1. Regulations and Guidelines Applicable to DDT, DDE, and DDD .......................................................... 369